Toku Inc.

About

Toku is creating a world focused on preventive healthcare, using the eye as a window to our health. We believe every person in the world should have access to early diagnosis of health conditions before it’s too late. How? by developing tools using AI and retinal images to enable accessible healthcare for early and accurate diagnosis of health conditions to empower everyday individuals. The retina has long been recognized as a unique window into an individual’s health, as the biomarkers present in retinal images may provide valuable insights into aging, inflammatory health, neurological health, and cardiovascular health. BioAge Not all people age equally. Every person has two ages: our chronological age (how old you are) and our biological age. Biological age (or BioAge) is a measure of how well our cells, tissues and organs are aging. Toku’s BioAge product determines a person’s biological age, which can give an indication of their overall health, by looking at vascular, metabolic, inflammatory and lifestyle indicators present in the retinal image. By knowing our BioAge earlier, we can make conscious health choices to improve our health. Unlike our chronological age, our BioAge is not fixed. BioAge uses retinal images and hence is non-invasive, time efficient, cost effective, and can be delivered by trusted healthcare providers. The retinal vasculature allows direct non-invasive visualization of the body’s microvasculature, as it is the only part of the body where scientists and clinicians can directly assess the health of an individual’s neuro-vascular tissues. Toku’s AI platform utilizes a revolutionary, patented method to evaluate more than 23 million technical parameters and 12 biological parameters in each retinal image, to produce a BioAge outcome. The AI engine has learned patterns from images from over 1.3 million retinal images to recognize the various features of health. Cardiovascular Screening (CLAiR) Cardiovascular disease is the leading caus

Product

Value proposition

Provides AI-powered retinal imaging solutions to assess biological age, cardiovascular risk, and kidney disease risk through retinal analysis.

Target customers

health systems, clinics, ophthalmology and primary care providers, diagnostic centers

Regulatory

BioAge: regulatory status varies by region; CLAiR: CE/UKCA; MyKidneyAI: regulatory status varies by region

Founders

• David Squirrell
• Ehsan Vaghefi

Categories

Products

Key features

Technologies

Integrations

Target conditions

Care settings

Certifications

Traction metrics

Competitors

Investors

News

• Topcon Healthcare, Inc. Signs Acquisition Agreement for Toku, Inc. to Expand Fast, Non-Invasive Chronic Disease Screening | Topcon Healthcare · 2025-10-17T11:00:00.000Z
• Toku Gets FDA Breakthrough Status for Tech That Identifies Chronic Kidney Disease Risk Through the Eye - aiineyecare.com · 2024-10-11T21:29:58.000Z
• Toku Eyes snapped up by Tokyo-listed Topcon Corporation · 2025-10-20T11:24:43.000Z
• Toku Inc. Series A Preferred Investment Round Led by Topcon Healthcare and National Vision, Inc. | Topcon Healthcare · 2024-12-10T17:44:11.000Z
• Topcon purchases Toku, Inc · 2025-10-21T16:04:49.000Z
• Topcon Signs Acquisition of Toku · 2025-10-17T14:51:40.000Z

Browse similar startups

Related startups

• TwoStep Therapeutics — San Carlos, CA
• UBF Consulting, Inc. — Walnut Creek, CA
• UCLA Center for Human Nutrition RFO Weight Management Program — Los Angeles, CA
• Unephra — San Jose, CA
• Unite Genomics — San Mateo, CA
• US-Japan MedTech Frontiers (now US-Japan Healthcare Connection) — Los Gatos, CA
• ViFive — Boulder, CO
• Vital Care Hospice House — Cheboygan, MI
• Wise IOT Solutions — San Diego, CA
• xStratum.ai — San Francisco, CA
• XYRO Health- Claims & Denial Management Platform — San Jose, CA
• AccurKardia — New York, NY